drugset / Trial / NCT01025596
Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.
Timeline
- Start
- 2007-05
- Primary completion
- 2011-02
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interleukin-7 | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |
| Subject | Interleukin-7 | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Subject | Interleukin-7 | Protein / enzyme biologic | 20 ug/kg | Subcutaneous |
| Subject | Interleukin-7 | Protein / enzyme biologic | 30 ug/kg | Subcutaneous |